Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more than 48 weeks(+8 weeks).
The study will start after investigator determines the administration of Olomax tablets based on the investigator's judgement and obtaining informed consent from the subject during subject's daily visit. The dose of the Olomax tablet for each subject will be determined based on efficacy and drug resistance according to the subject's previous drug administration. Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more than 48 weeks(+8 weeks). Efficacy of Olomax tablets will be evaluated based on the data collected from more than 24 weeks to 48 weeks(+8 weeks) from the baseline visit. Safety of Olomax tablets will be evaluated based on the adverse events collected during the study peroid.
Study Type
OBSERVATIONAL
Enrollment
5,450
Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
Hallym University Dongtan Sacred Heart Hospital
Hwaseong-si, Gyeonggi-do, South Korea
Blood pressure treatment goal achievement rate
Blood pressure treatment goal achievement rate: The percentage of patients observed for more than 24 weeks compared to the baseline whose blood pressure reached the target value
Time frame: more than 24 weeks
LDL-C treatment goal achievement rate
LDL-C treatment goal achievement rate: The percentage of patients observed for more than 24 weeks compared to the baseline whose LDL-C reached the target level
Time frame: more than 24 weeks
Change in blood pressure
Change in blood pressure at 24 to 48 weeks compared to baseline
Time frame: 24 to 48 weeks
The proportion of patients who have reached the treatment goal at baseline and maintain the change in blood pressure and treatment goal
The proportion of patients who have reached the treatment goal at baseline and maintain the change in blood pressure and treatment goal at 24 to 48 weeks
Time frame: 24 to 48 weeks
the percentage of patients maintaining the treatment goal and the amount of change in blood pressure
Among patients who reached the treatment goal at baseline, the percentage of patients maintaining the treatment goal and the amount of change in blood pressure at 24 to 48 weeks for each antihypertensive drug (single, double drug combination classification)
Time frame: 24 to 48 weeks
Patients who did not reach the treatment goal at baseline, change in blood pressure and rate of reaching the treatment goal
Patients who did not reach the treatment goal at baseline, change in blood pressure and rate of reaching the treatment goal at 24 to 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 24 to 48 weeks
For patients who did not reach the treatment goal at baseline, the amount of change in blood pressure and the rate of reaching the treatment goal
For patients who did not reach the treatment goal at baseline, the amount of change in blood pressure and the rate of reaching the treatment goal at 24 to 48 weeks by antihypertensive drug (single, combined classification)
Time frame: 24 to 48 weeks
Change in LDL-C
Change in LDL-C at 24 to 48 weeks compared to baseline
Time frame: 24 to 48 weeks
Among patients who reached the treatment goal at baseline, the change in LDL-C, the proportion of patients maintaining the treatment goal
Among patients who reached the treatment goal at baseline, the change in LDL-C at 24 to 48 weeks and the proportion of patients maintaining the treatment goal
Time frame: 24 to 48 weeks
Among patients who reached the treatment goal at baseline, the change in LDL-C , the proportion of eligible patients maintaining the treatment goal
Among patients who reached the treatment goal at baseline, the change in LDL-C at 24 to 48 weeks for each anti-dyslipidemia agent and the proportion of eligible patients maintaining the treatment goal
Time frame: 24 to 48 weeks
For patients who did not reach the treatment goal at baseline, change in LDL-C, rate of reaching the treatment goal
For patients who did not reach the treatment goal at baseline, change in LDL-C and rate of reaching the treatment goal at 24 to 48 weeks
Time frame: 24 to 48 weeks
For patients who did not reach the treatment goal at baseline, change in LDL-C, rate of reaching the treatment goal
For patients who did not reach the treatment goal at baseline, change in LDL-C and rate of reaching the treatment goal at 24 to 48 weeks for each anti-dyslipidemia agent
Time frame: 24 to 48 weeks
Change amount and rate of change in lipid variables
Change amount and rate of change in lipid variables (Non-HDL, HDL-C, TG, TC) at 24 to 48 weeks compared to the baseline
Time frame: 24 to 48 weeks
the rate and amount of change in both blood pressure and LDL-C
Patients who underwent FU for more than 24 weeks compared to the baseline, the rate and amount of change in both blood pressure and LDL-C reached the target values
Time frame: more than 24 weeks
Change in Framingham Risk Score (FRS)
Change in Framingham Risk Score (FRS) over 24 weeks compared to baseline
Time frame: more than 24 weeks
change in carotid intima-media thickening (CIMT) value
If data exists, change in carotid intima-media thickening (CIMT) value over 24 weeks compared to baseline
Time frame: more than 24 weeks
hsCRP change
If information is collected, hsCRP change over 24 weeks compared to baseline
Time frame: more than 24 weeks